Dow Jones
33.849,46 -497,57 (-1,45%) Nasdaq
11.049,50 -176,86 (-1,58%) Nikkei 225
28.027,15 -135,68 (-0,48%) EUR/USD
1,0364 +0,0019 (+0,19%) BTC-EUR
15.694,13 +23,38 (+0,15%) CMC Crypto 200
382,54 +2,25 (+0,59%)
Cerevel Therapeutics Holdings, Inc. (CERE)
Dopo ore:
| Chiusura precedente | 28,51 |
| Aperto | 28,46 |
| Denaro | 27,72 x 1200 |
| Lettera | 30,42 x 800 |
| Min-Max giorno | 27,60 - 29,12 |
| Intervallo di 52 settimane | 19,86 - 41,46 |
| Volume | |
| Media Volume | 583.654 |
| Capitalizzazione | 4,346B |
| Beta (5 anni mensile) | 1,64 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,71 |
| Prossima data utili | 27 feb 2023 - 03 mar 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 40,40 |
- GlobeNewswire
Cerevel Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences. Event: Guggenheim Healthcare Talks 4th Annual Immunology & Neurology DayDate: Tuesday, November 15, 2022Format: One-on-one meetings Event: Stifel 2022 Healthcare ConferenceDate: Wednesday, November 16, 2022Format:
- GlobeNewswire
Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with schizophrenia Received FDA Fast Track designation for emraclidine in Alzheimer’s disease psychosis; Phase 1 trial in healthy, elderly volunteers to be initiated by year-end Cash, cash equivalents and marketable securities of $1,030 million as of September 30, 2022, expected to support opera
- GlobeNewswire
Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8, 2022, before the U.S. financial markets open. Management will host a conference call to discuss third quarter 2022 financial results and recent business updates on Tuesday, November 8, 2022, at 8:00 a.m. ET. To access the call
